In the present work, we propose a model-informed approach for the optimization of MACE endpoint, based on a model-based meta-analysis of anti-hypercholesterolemia trials involving statin and anti-PCSK9 drugs. Here, PCSK9 is linked to familial hypercholesterolemia.